免疫治疗最新进展PPT课件.ppt

免疫治疗新进展
PD-1/PD-L1抑制剂
——Nivolumab
——Pembrolizumab
——Atezolizumab
——MEDI4736等
CAR-T疗法
——开启精准治疗时代
Nivolumab对比多西他赛用于经治晚期或转移性非小细胞肺癌鳞癌III期临床研究:CheckMate 017
Brahmer et al. N Engl J Med, 2015;373(2):123-135
Nivolumab improves pared to Docetaxel in Advanced Squamous-Cell NSCLC
Nivolumab
Docetaxel
Hazard ratio(95% Cl)
P-value
N
135
137
(,)

Number of deaths
86
113
Median OS,
Month(95% Cl)
(,)
6(,)
1-year OS(95% Cl)
42(34-50)
24(17-31)
Brahmer et al. N Engl J Med, 2015;373(2):123-135
Nivolumab improves pared to Docetaxel in Advanced Squamous-Cell NSCLC
Nivolumab
Docetaxel
Hazard ratio(95% Cl)
P-value
N
135
137
(,)

Number of events
105
122
Median PFS,
Month(95% Cl)
(,)
(,)
1-year PFS(95% Cl)
21(14-28)
6(3-12)
Brahmer et al. N Engl J Med, 2015;373(2):123-135
Treatment-Related Adverse Events Reported in at Least 5% of Patients
Nivolumab
Docetaxel
Number of events
131
129
Any Grade
76
111
Grade3 or 4
9
71
Brahmer et al. N Engl J Med, 2015;373(2):123-135
PD-L1 expression was neither prognostic nor predictive of efficacy in patients with squamous-cell NSCLC
Brahmer et al. N Engl J Med, 2015;373(2):123-135
Nivolumab对比多西他赛治疗晚期非鳞NSCLC的随机III期临床研究:CheckMate 057试验结果
Luis Paz-Ares, et al. ASCO 2015 LAB109
主要终点:OS
Luis Paz-Ares, et al. ASCO 2015 LAB109
OS: 根据基线PD-L1表达量
Luis Paz-Ares, et al. ASCO 2015 LAB109